NCT04683445: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy, Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have started eribulin treatment between January-December 2021
Exclusions: Patients who have received more than 2 lines of chemotherapy for metastatic breast cancer; Patients with central nervous system metastasis

Comments are closed.

Up ↑